FDA Adverse Event Injury Summary report: N

VERCISE? CARTESIA?

MDR report key: 22029668 · Received May 15, 2025

Report

Report Number
3006630150-2025-03387
Event Type
Injury
Date Received
May 15, 2025
Date of Event
April 20, 2025
Report Date
September 25, 2025
Manufacturer
BOSTON SCIENTIFIC NEUROMODULATION CORPORATION
Product Code
NHL
PMA / PMN Number
P150031
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
TU
Reporter Occupation
PHYSICIAN
Health Professional
Yes

Narratives

Additional Manufacturer Narrative · 0

ADDITIONAL SUSPECT MEDICAL DEVICE COMPONENT INVOLVED IN THE EVENT: PRODUCT FAMILY: DBS-LINEAR LEADS. UPN: M365DB2202450. MODEL: DB-2202-45. SERIAL: (B)(6). BATCH: 7130787. UDI: (B)(4).

Additional Manufacturer Narrative · 0

ADDITIONAL SUSPECT MEDICAL DEVICE COMPONENT INVOLVED IN THE EVENT: PRODUCT FAMILY: DBS-LINEAR LEADS UPN: M365DB2202450 MODEL: DB-2202-45 SERIAL: (B)(6) BATCH: 7130787 UDI: (B)(4).

Additional Manufacturer Narrative · 0

CORRECTION TO INITIAL REPORT IN BLOCK: H11. ADDITIONAL SUSPECT MEDICAL DEVICE COMPONENT INVOLVED IN THE EVENT: PRODUCT FAMILY: DBS-LINEAR LEADS. UPN: M365DB2202450. MODEL: DB-2202-45. SERIAL: (B)(6). BATCH: (B)(6). UDI: (B)(4).

Description of Event or Problem · 0

IT WAS REPORTED THAT THE DAY AFTER UNDERGOING A DEEP BRAIN STIMULATION (DBS) IMPLANT PROCEDURE, THE PATIENT DEVELOPED BILATERAL EDEMA AT BOTH THE DISTAL AND PROXIMAL SEGMENTS OF THE LEADS, LEADING TO INFLAMMATION, PAIN, A BURNING AND STINGING SENSATION, AND DISCHARGE. BLOOD TESTS SHOWED NO ABNORMALITIES. IMAGING WAS CONDUCTED TO ACCURATELY DETERMINE THE LOCATION OF THE EDEMA, AND APPROPRIATE MEDICATION WAS ADMINISTERED TO MANAGE THE CONDITION. THE SWELLING HAS SINCE DIMINISHED WITH TREATMENT, AND THE PATIENT IS EXPECTED TO MAKE A FULL RECOVERY. ADDITIONAL INFORMATION WAS RECEIVED THAT THE ADMINISTRATION OF STEROIDS LED TO SIGNIFICANT SYMPTOM RESOLUTION.

Description of Event or Problem · 0

IT WAS REPORTED THAT THE DAY AFTER UNDERGOING A DEEP BRAIN STIMULATION (DBS) IMPLANT PROCEDURE, THE PATIENT DEVELOPED BILATERAL EDEMA AT BOTH THE DISTAL AND PROXIMAL SEGMENTS OF THE LEADS, LEADING TO INFLAMMATION, PAIN, A BURNING AND STINGING SENSATION, AND DISCHARGE. BLOOD TESTS SHOWED NO ABNORMALITIES. IMAGING WAS CONDUCTED TO ACCURATELY DETERMINE THE LOCATION OF THE EDEMA, AND APPROPRIATE MEDICATION WAS ADMINISTERED TO MANAGE THE CONDITION. THE SWELLING HAS SINCE DIMINISHED WITH TREATMENT, AND THE PATIENT IS EXPECTED TO MAKE A FULL RECOVERY.

Description of Event or Problem · 0

IT WAS REPORTED THAT THE DAY AFTER UNDERGOING A DEEP BRAIN STIMULATION (DBS) IMPLANT PROCEDURE, THE PATIENT DEVELOPED BILATERAL EDEMA AT BOTH THE DISTAL AND PROXIMAL SEGMENTS OF THE LEADS, LEADING TO INFLAMMATION, PAIN, A BURNING AND STINGING SENSATION, AND DISCHARGE. BLOOD TESTS SHOWED NO ABNORMALITIES. IMAGING WAS CONDUCTED TO ACCURATELY DETERMINE THE LOCATION OF THE EDEMA, AND APPROPRIATE MEDICATION WAS ADMINISTERED TO MANAGE THE CONDITION. THE SWELLING HAS SINCE DIMINISHED WITH TREATMENT, AND THE PATIENT IS EXPECTED TO MAKE A FULL RECOVERY. ADDITIONAL INFORMATION WAS RECEIVED THAT THE ADMINISTRATION OF STEROIDS LED TO SIGNIFICANT SYMPTOM RESOLUTION. ADDITIONAL INFORMATION WAS RECEIVED THAT THE PATIENT DEVELOPED BILATERAL PERI-LEAD EDEMA TWO MONTHS FOLLOWING THE DBS LEAD IMPLANTATION PROCEDURE. THE EDEMA PERSISTED FOR APPROXIMATELY THREE MONTHS AND WAS ASSOCIATED WITH WORSENING PARKINSONS DISEASE SYMPTOMS, IMBALANCE, AND A LEFT-SIDED SUBARACHNOID HEMORRHAGE. CORTICOSTEROID THERAPY WAS ADMINISTERED, AND RESOLUTION OF THE EVENT WAS CONFIRMED BY IMAGING AFTER THREE MONTHS. HOWEVER, CLINICAL IMBALANCE PERSISTS. THE DBS SYSTEM REMAINS ACTIVE, AND THE PATIENT CONTINUES TO EXPERIENCE THERAPEUTIC BENEFIT.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
88758 VERCISE? CARTESIA? STIMULATOR, ELECTRICAL, IMPLANTED, FOR PARKINSONIAN TREMOR NHL BOSTON SCIENTIFIC NEUROMODULATION CORPORATION DB-2202-45 7130897

Patients

Seq Age Sex Outcome Treatment
1 NA Unknown Required Intervention